{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:46:26Z","timestamp":1793112386967,"version":"4.5.0"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["Intramural Program"],"award-info":[{"award-number":["Intramural Program"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Alzheimer\u2019s disease (AD) is one of the most common and devastating neurodegenerative diseases, characterized by accumulation of amyloid-beta (A\u03b2) plaques, neurofibrillary tangles of tau protein, and persistence of neuroinflammation, leading to progressive cognitive decline, loss of independence, emotional and financial strain on families, and significant societal costs. Current anti-amyloid treatments are partly successful in removing A\u03b2 amyloid, but often lead to increased inflammation. This leads to limited therapeutic efficacy and causes side effects such as amyloid-related imaging abnormalities. In addition, they do not address neuroinflammation in AD patients. In this review, we discuss a new therapeutic strategy that combines single-domain antibodies (sdAbs, nanobodies) against A\u03b2 fibrils and anti-inflammatory drugs and applies them to the regions of neuroinflammation associated with the plaques in AD patients. This strategy aims to control the function of activated microglia and astrocytes, thereby avoiding unnecessary immunosuppression. We also discuss the unique features of sdAbs, including small size, good tissue penetration, and lack of Fc-mediated immune reactions, as well as relevant payloads (i.e., small molecules, biologics, and nanoparticles) and delivery systems. This immunomodulatory therapy targets the plaques specifically and therefore represents a promising opportunity to improve amyloid clearance and target the inflammatory components of AD, potentially improving the therapeutic efficacy of the disease.<\/jats:p>","DOI":"10.1186\/s40035-025-00513-5","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T03:20:20Z","timestamp":1760325620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Beyond amyloid: nanobody-mediated neuroinflammatory therapy for Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"14","author":[{"given":"Soukaina","family":"Amniouel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-9158","authenticated-orcid":false,"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"issue":"1","key":"513_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00269-y","volume":"7","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, Amieva H, Petersen RC, Chetelat G, Holtzman DM, Hyman BT, et al. Alzheimer disease. Nat Rev Dis Primers. 2021;7(1):33.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"513_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"F Leng","year":"2021","unstructured":"Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17(3):157\u201372.","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"513_CR3","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/nm.3913","volume":"21","author":"E Zenaro","year":"2015","unstructured":"Zenaro E, Pietronigro E, Bianca VD, Piacentino G, Marongiu L, Budui S, et al. Neutrophils promote Alzheimer\u2019s disease\u2013like pathology and cognitive decline via LFA-1 integrin. Nat Med. 2015;21(8):880\u20136.","journal-title":"Nat Med"},{"key":"513_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nbd.2016.07.007","volume":"107","author":"E Zenaro","year":"2017","unstructured":"Zenaro E, Piacentino G, Constantin G. The blood-brain barrier in Alzheimer\u2019s disease. Neurobiol Dis. 2017;107:41\u201356.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"513_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-015-0125-2","volume":"7","author":"P Th\u00e9riault","year":"2015","unstructured":"Th\u00e9riault P, ElAli A, Rivest S. The dynamics of monocytes and microglia in Alzheimer\u2019s disease. Alzheimers Res Ther. 2015;7(1):41.","journal-title":"Alzheimers Res Ther"},{"key":"513_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2024.106461","volume":"193","author":"J Zeng","year":"2024","unstructured":"Zeng J, Liao Z, Yang H, Wang Q, Wu Z, Hua F, et al. T cell infiltration mediates neurodegeneration and cognitive decline in Alzheimer\u2019s disease. Neurobiol Dis. 2024;193:106461.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"513_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40035-025-00478-5","volume":"14","author":"B Sun","year":"2025","unstructured":"Sun B, Li L, Harris OA, Luo J. Blood\u2013brain barrier disruption: a pervasive driver and mechanistic link between traumatic brain injury and Alzheimer\u2019s disease. Transl Neurodegen. 2025;14(1):16.","journal-title":"Transl Neurodegen"},{"issue":"1","key":"513_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","volume":"8","author":"W Zhang","year":"2023","unstructured":"Zhang W, Xiao D, Mao Q, Xia H. Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther. 2023;8(1):267.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"513_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","volume":"9","author":"HS Kwon","year":"2020","unstructured":"Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020;9(1):42.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"513_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12974-024-03163-y","volume":"21","author":"S Lista","year":"2024","unstructured":"Lista S, Imbimbo BP, Grasso M, Fidilio A, Emanuele E, Minoretti P, et al. Tracking neuroinflammatory biomarkers in Alzheimer\u2019s disease: a strategy for individualized therapeutic approaches? J Neuroinflammation. 2024;21(1):187.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"513_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/jamaneurol.2024.3937","volume":"82","author":"S Salloway","year":"2025","unstructured":"Salloway S, Wojtowicz J, Voyle N, Lane CA, Klein G, Lyons M, et al. Amyloid-related imaging abnormalities (ARIA) in clinical trials of gantenerumab in early Alzheimer disease. JAMA Neurol. 2025;82(1):19\u201329.","journal-title":"JAMA Neurol"},{"issue":"1","key":"513_CR12","first-page":"106","volume":"87","author":"HM Arrighi","year":"2016","unstructured":"Arrighi HM, Barakos J, Barkhof F, Tampieri D, Jack C Jr, Melancon D, et al. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer\u2019s disease treated with bapineuzumab: a historical, prospective secondary analysis. J Neurol Neurosurg Psychiatry. 2016;87(1):106\u201312.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"513_CR13","first-page":"15","volume":"2","author":"BP Imbimbo","year":"2010","unstructured":"Imbimbo BP, Solfrizzi V, Panza F. Are NSAIDs useful to treat Alzheimer\u2019s disease or mild cognitive impairment? Front Aging Neurosci. 2010;2:15\u20137.","journal-title":"Front Aging Neurosci."},{"issue":"Suppl2","key":"513_CR14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/jnc.13583","volume":"139","author":"TE Golde","year":"2016","unstructured":"Golde TE. Overcoming translational barriers impeding development of Alzheimer\u2019s disease modifying therapies. J Neurochem. 2016;139(Suppl2):224\u201336.","journal-title":"J Neurochem"},{"issue":"8","key":"513_CR15","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1517\/13543780903066780","volume":"18","author":"BP Imbimbo","year":"2009","unstructured":"Imbimbo BP. An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer\u2019s disease. Expert Opin Investig Drugs. 2009;18(8):1147\u201368.","journal-title":"Expert Opin Investig Drugs"},{"key":"513_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-11-120","volume":"11","author":"ER Zimmer","year":"2014","unstructured":"Zimmer ER, Leuzy A, Benedet AL, Breitner J, Gauthier S, Rosa-Neto P. Tracking neuroinflammation in Alzheimer\u2019s disease: the role of positron emission tomography imaging. J Neuroinflammation. 2014;11:120.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"513_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neuron.2014.05.041","volume":"83","author":"CM Karch","year":"2014","unstructured":"Karch CM, Cruchaga C, Goate AM. Alzheimer\u2019s disease genetics: from the bench to the clinic. Neuron. 2014;83(1):11\u201326.","journal-title":"Neuron"},{"issue":"4","key":"513_CR18","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","volume":"54","author":"C Bellenguez","year":"2022","unstructured":"Bellenguez C, K\u00fc\u00e7\u00fckali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias. Nat Genetics. 2022;54(4):412\u201336.","journal-title":"Nat Genetics"},{"issue":"9","key":"513_CR19","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1474-4422(11)70156-9","volume":"10","author":"ME Murray","year":"2011","unstructured":"Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer\u2019s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10(9):785\u201396.","journal-title":"Lancet Neurol"},{"issue":"2","key":"513_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00401-014-1375-y","volume":"129","author":"DR Thal","year":"2015","unstructured":"Thal DR, Walter J, Saido TC, F\u00e4ndrich M. Neuropathology and biochemistry of A\u03b2 and its aggregates in Alzheimer\u2019s disease. Acta Neuropathol. 2015;129(2):167\u201382.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"513_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12974-023-02853-3","volume":"20","author":"Y Chen","year":"2023","unstructured":"Chen Y, Yu Y. Tau and neuroinflammation in Alzheimer\u2019s disease: interplay mechanisms and clinical translation. J Neuroinflammation. 2023;20(1):165.","journal-title":"J Neuroinflammation"},{"issue":"Pt 2","key":"513_CR22","first-page":"288","volume":"132","author":"H Neumann","year":"2009","unstructured":"Neumann H, Kotter MR, Franklin RJ. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain. 2009;132(Pt 2):288\u201395.","journal-title":"Brain"},{"issue":"4","key":"513_CR23","first-page":"1537","volume":"15","author":"Q Deng","year":"2024","unstructured":"Deng Q, Wu C, Parker E, Liu TC, Duan R, Yang L. Microglia and astrocytes in Alzheimer\u2019s disease: significance and summary of recent advances. Aging Dis. 2024;15(4):1537\u201364.","journal-title":"Aging Dis"},{"issue":"1","key":"513_CR24","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","volume":"8","author":"C Gao","year":"2023","unstructured":"Gao C, Jiang J, Tan Y, Chen S. Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduct Target Ther. 2023;8(1):359.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"513_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.brainresbull.2011.10.004","volume":"87","author":"JA Smith","year":"2012","unstructured":"Smith JA, Das A, Ray SK, Banik NL. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull. 2012;87(1):10\u201320.","journal-title":"Brain Res Bull"},{"key":"513_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1750-1326-6-45","volume":"6","author":"XD Pan","year":"2011","unstructured":"Pan XD, Zhu YG, Lin N, Zhang J, Ye QY, Huang HP, et al. Microglial phagocytosis induced by fibrillar beta-amyloid is attenuated by oligomeric beta-amyloid: implications for Alzheimer\u2019s disease. Mol Neurodegener. 2011;6:45.","journal-title":"Mol Neurodegener"},{"issue":"8","key":"513_CR27","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3390\/antiox9080743","volume":"9","author":"DSA Simpson","year":"2020","unstructured":"Simpson DSA, Oliver PL. ROS generation in microglia: understanding oxidative stress and inflammation in neurodegenerative disease. Antioxidants.\u00a02020;9(8):743.","journal-title":"Antioxidants"},{"issue":"2","key":"513_CR28","first-page":"682","volume":"43","author":"SY Kim","year":"2019","unstructured":"Kim SY, Jin CY, Kim CH, Yoo YH, Choi SH, Kim GY, et al. Isorhamnetin alleviates lipopolysaccharide-induced inflammatory responses in BV2 microglia by inactivating NF-kappaB, blocking the TLR4 pathway and reducing ROS generation. Int J Mol Med. 2019;43(2):682\u201392.","journal-title":"Int J Mol Med"},{"issue":"1","key":"513_CR29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen H, Li R, Sterling K, Song W. Amyloid beta-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct Target Ther. 2023;8(1):248.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"513_CR30","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell. 2017;169(7):1276-90.e17.","journal-title":"Cell"},{"issue":"3","key":"513_CR31","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","volume":"47","author":"S Krasemann","year":"2017","unstructured":"Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47(3):566-81.e9.","journal-title":"Immunity"},{"key":"513_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104956","volume":"142","author":"BT Casali","year":"2020","unstructured":"Casali BT, MacPherson KP, Reed-Geaghan EG, Landreth GE. Microglia depletion rapidly and reversibly alters amyloid pathology by modification of plaque compaction and morphologies. Neurobiol Dis. 2020;142:104956.","journal-title":"Neurobiol Dis"},{"issue":"8","key":"513_CR33","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1523\/JNEUROSCI.2594-19.2020","volume":"40","author":"KM Onuska","year":"2020","unstructured":"Onuska KM. The dual role of microglia in the progression of Alzheimer\u2019s disease. J Neurosci. 2020;40(8):1608\u201310.","journal-title":"J Neurosci"},{"issue":"10","key":"513_CR34","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/s41593-021-00931-4","volume":"24","author":"R Wright","year":"2021","unstructured":"Wright R. Microglia set the pace for tau spread. Nat Neurosci. 2021;24(10):1342.","journal-title":"Nat Neurosci"},{"issue":"11","key":"513_CR35","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1038\/s41591-021-01568-3","volume":"27","author":"TA Pascoal","year":"2021","unstructured":"Pascoal TA, Benedet AL, Ashton NJ, Kang MS, Therriault J, Chamoun M, et al. Publisher correction: Microglial activation and tau propagate jointly across Braak stages. Nat Med. 2021;27(11):2048\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"513_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-025-00810-7","volume":"20","author":"HK Gildea","year":"2025","unstructured":"Gildea HK, Liddelow SA. Mechanisms of astrocyte aging in reactivity and disease. Mol Neurodegener. 2025;20(1):21.","journal-title":"Mol Neurodegener"},{"key":"513_CR37","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.170228","author":"GR Frost","year":"2017","unstructured":"Frost GR, Li YM. The role of astrocytes in amyloid production and Alzheimer\u2019s disease. Open Biol. 2017. https:\/\/doi.org\/10.1098\/rsob.170228.","journal-title":"Open Biol"},{"issue":"12","key":"513_CR38","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1038\/s41593-024-01791-4","volume":"27","author":"A Serrano-Pozo","year":"2024","unstructured":"Serrano-Pozo A, Li H, Li Z, Mu\u00f1oz-Castro C, Jaisa-aad M, Healey MA, et al. Astrocyte transcriptomic changes along the spatiotemporal progression of Alzheimer\u2019s disease. Nat Neurosci. 2024;27(12):2384\u2013400.","journal-title":"Nat Neurosci"},{"issue":"7638","key":"513_CR39","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481\u20137.","journal-title":"Nature"},{"issue":"1","key":"513_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-023-01526-9","volume":"11","author":"JM Lawrence","year":"2023","unstructured":"Lawrence JM, Schardien K, Wigdahl B, Nonnemacher MR. Roles of neuropathology-associated reactive astrocytes: a systematic review. Acta Neuropathol Commun. 2023;11(1):42.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"513_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13311-022-01185-z","volume":"19","author":"R Duara","year":"2022","unstructured":"Duara R, Barker W. Heterogeneity in Alzheimer\u2019s disease diagnosis and progression rates: implications for therapeutic trials. Neurotherapeutics. 2022;19(1):8\u201325.","journal-title":"Neurotherapeutics"},{"issue":"7761","key":"513_CR42","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41586-019-1195-2","volume":"570","author":"H Mathys","year":"2019","unstructured":"Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, et al. Single-cell transcriptomic analysis of Alzheimer\u2019s disease. Nature. 2019;570(7761):332\u20137.","journal-title":"Nature"},{"issue":"4","key":"513_CR43","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00401-013-1182-x","volume":"126","author":"S Prokop","year":"2013","unstructured":"Prokop S, Miller KR, Heppner FL. Microglia actions in Alzheimer\u2019s disease. Acta Neuropathol. 2013;126(4):461\u201377.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"513_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01486-5","volume":"8","author":"W Zhang","year":"2023","unstructured":"Zhang W, Xiao D, Mao Q, Xia H. Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther. 2023;8(1):267.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"513_CR45","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol. 2015;14(4):388\u2013405.","journal-title":"Lancet Neurol"},{"issue":"1","key":"513_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0353-3","volume":"10","author":"F Brosseron","year":"2018","unstructured":"Brosseron F, Trasch\u00fctz A, Widmann CN, Kummer MP, Tacik P, Santarelli F, et al. Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer\u2019s disease. Alzheimers Res Ther. 2018;10(1):25.","journal-title":"Alzheimers Res Ther"},{"key":"513_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-11-48","volume":"11","author":"D Doens","year":"2014","unstructured":"Doens D, Fern\u00e1ndez PL. Microglia receptors and their implications in the response to amyloid \u03b2 for Alzheimer\u2019s disease pathogenesis. J Neuroinflammation. 2014;11:48.","journal-title":"J Neuroinflammation"},{"key":"513_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.00444","volume":"14","author":"W Cui","year":"2020","unstructured":"Cui W, Sun C, Ma Y, Wang S, Wang X, Zhang Y. Inhibition of TLR4 induces M2 microglial polarization and provides neuroprotection via the NLRP3 inflammasome in Alzheimer\u2019s disease. Front Neurosci. 2020;14:444.","journal-title":"Front Neurosci"},{"issue":"1","key":"513_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-025-00828-x","volume":"20","author":"MR Duggan","year":"2025","unstructured":"Duggan MR, Morgan DG, Price BR, Rajbanshi B, Martin-Pe\u00f1a A, Tansey MG, et al. Immune modulation to treat Alzheimer\u2019s disease. Mol Neurodegener. 2025;20(1):39.","journal-title":"Mol Neurodegener"},{"issue":"6","key":"513_CR50","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","volume":"12","author":"V Calsolaro","year":"2016","unstructured":"Calsolaro V, Edison P. Neuroinflammation in Alzheimer\u2019s disease: current evidence and future directions. Alzheimers Dement. 2016;12(6):719\u201332.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"513_CR51","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1212\/01.wnl.0000244749.20056.d4","volume":"68","author":"P Edison","year":"2007","unstructured":"Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007;68(7):501\u20138.","journal-title":"Neurology"},{"issue":"1","key":"513_CR52","doi-asserted-by":"publisher","first-page":"8220","DOI":"10.1038\/s41467-023-43933-5","volume":"14","author":"E Solopova","year":"2023","unstructured":"Solopova E, Romero-Fernandez W, Harmsen H, Ventura-Antunes L, Wang E, Shostak A, et al. Fatal iatrogenic cerebral beta-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer\u2019s disease. Nat Commun. 2023;14(1):8220.","journal-title":"Nat Commun"},{"issue":"1","key":"513_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61691-2","volume":"14","author":"L Soderberg","year":"2024","unstructured":"Soderberg L, Johannesson M, Gkanatsiou E, Nygren P, Fritz N, Zachrisson O, et al. Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities. Sci Rep. 2024;14(1):10868.","journal-title":"Sci Rep"},{"issue":"1","key":"513_CR54","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1212\/01.wnl.0000284596.95156.48","volume":"70","author":"CA Szekely","year":"2008","unstructured":"Szekely CA, Breitner JC, Fitzpatrick AL, Rea TD, Psaty BM, Kuller LH, et al. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology. 2008;70(1):17\u201324.","journal-title":"Neurology"},{"issue":"5","key":"513_CR55","volume":"11","author":"MM Ali","year":"2019","unstructured":"Ali MM, Ghouri RG, Ans AH, Akbar A, Toheed A. Recommendations for anti-inflammatory treatments in Alzheimer\u2019s disease: a comprehensive review of the literature. Cureus. 2019;11(5):e4620.","journal-title":"Cureus"},{"issue":"4","key":"513_CR56","first-page":"CD011459","volume":"4","author":"F Jordan","year":"2020","unstructured":"Jordan F, Quinn TJ, McGuinness B, Passmore P, Kelly JP, Tudur Smith C, et al. Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. Cochrane Database Syst Rev. 2020;4(4):CD011459.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"513_CR57","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/gps.4871","volume":"33","author":"JO Ekert","year":"2018","unstructured":"Ekert JO, Gould RL, Reynolds G, Howard RJ. TNF alpha inhibitors in Alzheimer\u2019s disease: a systematic review. Int J Geriatr Psychiatry. 2018;33(5):688\u201394.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3A","key":"513_CR58","doi-asserted-by":"publisher","first-page":"2S","DOI":"10.1016\/S0002-9343(97)00203-9","volume":"104","author":"JR Vane","year":"1998","unstructured":"Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104(3A):2S-8S.","journal-title":"Am J Med"},{"issue":"6","key":"513_CR59","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1177\/1535370218787770","volume":"244","author":"RM Haley","year":"2019","unstructured":"Haley RM, von Recum HA. Localized and targeted delivery of NSAIDs for treatment of inflammation: a review. Exp Biol Med (Maywood). 2019;244(6):433\u201344.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"7618","key":"513_CR60","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136.","journal-title":"Nature"},{"issue":"1","key":"513_CR61","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CHV Dyck","year":"2023","unstructured":"Dyck CHV, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"513_CR62","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3\u201314.","journal-title":"NeuroRx"},{"issue":"7","key":"513_CR63","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.addr.2011.12.005","volume":"64","author":"WA Banks","year":"2012","unstructured":"Banks WA. Drug delivery to the brain in Alzheimer\u2019s disease: consideration of the blood-brain barrier. Adv Drug Deliv Rev. 2012;64(7):629\u201339.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"513_CR64","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.nano.2011.03.008","volume":"7","author":"D Brambilla","year":"2011","unstructured":"Brambilla D, Le Droumaguet B, Nicolas J, Hashemi SH, Wu LP, Moghimi SM, et al. Nanotechnologies for Alzheimer\u2019s disease: diagnosis, therapy, and safety issues. Nanomedicine. 2011;7(5):521\u201340.","journal-title":"Nanomedicine"},{"key":"513_CR65","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","volume":"235","author":"C Saraiva","year":"2016","unstructured":"Saraiva C, Pra\u00e7a C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: overcoming blood\u2013brain barrier to treat neurodegenerative diseases. J Control Release. 2016;235:34\u201347.","journal-title":"J Control Release"},{"issue":"8","key":"513_CR66","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1212\/WNL.43.8.1609","volume":"43","author":"J Rogers","year":"1993","unstructured":"Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, et al. Clinical trial of indomethacin in Alzheimer\u2019s disease. Neurology. 1993;43(8):1609\u201311.","journal-title":"Neurology"},{"issue":"10","key":"513_CR67","doi-asserted-by":"publisher","first-page":"787","DOI":"10.7326\/0003-4819-115-10-787","volume":"115","author":"SE Gabriel","year":"1991","unstructured":"Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115(10):787\u201396.","journal-title":"Ann Intern Med"},{"issue":"11","key":"513_CR68","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41569-019-0225-y","volume":"16","author":"C Patrono","year":"2019","unstructured":"Patrono C, Baigent C. Role of aspirin in primary prevention of cardiovascular disease. Nat Rev Cardiol. 2019;16(11):675\u201386.","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"513_CR69","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S1474-4422(02)00133-3","volume":"1","author":"PS Aisen","year":"2002","unstructured":"Aisen PS. The potential of anti-inflammatory drugs for the treatment of Alzheimer\u2019s disease. Lancet Neurol. 2002;1(5):279\u201384.","journal-title":"Lancet Neurol"},{"issue":"4","key":"513_CR70","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jalz.2010.12.014","volume":"7","author":"JC Breitner","year":"2011","unstructured":"Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, et al. Extended results of the Alzheimer\u2019s disease anti-inflammatory prevention trial. Alzheimers Dement. 2011;7(4):402\u201311.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"513_CR71","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/psyg.12944","volume":"23","author":"A Rahman","year":"2023","unstructured":"Rahman A, Hossen MA, Chowdhury MFI, Bari S, Tamanna N, Sultana SS, et al. Aducanumab for the treatment of Alzheimer\u2019s disease: a systematic review. Psychogeriatrics. 2023;23(3):512\u201322.","journal-title":"Psychogeriatrics"},{"key":"513_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1169499","volume":"15","author":"Y Qiao","year":"2023","unstructured":"Qiao Y, Chi Y, Zhang Q, Ma Y. Safety and efficacy of lecanemab for Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized clinical trials. Front Aging Neurosci. 2023;15:1169499.","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"513_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01124-2","volume":"14","author":"E McDade","year":"2022","unstructured":"McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M, et al. Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022;14(1):191.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"513_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-021-00750-5","volume":"11","author":"G Bao","year":"2021","unstructured":"Bao G, Tang M, Zhao J, Zhu X. Nanobody: a promising toolkit for molecular imaging and disease therapy. EJNMMI Res. 2021;11(1):6.","journal-title":"EJNMMI Res"},{"issue":"1","key":"513_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-020-00226-z","volume":"17","author":"Y Wouters","year":"2020","unstructured":"Wouters Y, Jaspers T, De Strooper B, Dewilde M. Identification and in vivo characterization of a brain-penetrating nanobody. Fluids Barriers CNS. 2020;17(1):62.","journal-title":"Fluids Barriers CNS"},{"key":"513_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.978513","volume":"13","author":"F Zheng","year":"2022","unstructured":"Zheng F, Pang Y, Li L, Pang Y, Zhang J, Wang X, et al. Applications of nanobodies in brain diseases. Front Immunol. 2022;13:978513.","journal-title":"Front Immunol"},{"key":"513_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104249","volume":"84","author":"EE Congdon","year":"2022","unstructured":"Congdon EE, Pan R, Jiang Y, Sandusky-Beltran LA, Dodge A, Lin Y, et al. Single domain antibodies targeting pathological tau protein: influence of four IgG subclasses on efficacy and toxicity. EBioMedicine. 2022;84:104249.","journal-title":"EBioMedicine"},{"issue":"1","key":"513_CR78","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13195-023-01361-z","volume":"16","author":"A Bigi","year":"2024","unstructured":"Bigi A, Napolitano L, Vadukul DM, Chiti F, Cecchi C, Aprile FA, et al. A single-domain antibody detects and neutralises toxic Abeta(42) oligomers in the Alzheimer\u2019s disease CSF. Alzheimers Res Ther. 2024;16(1):13.","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"513_CR79","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","volume":"15","author":"RC Coll","year":"2019","unstructured":"Coll RC, Hill JR, Day CJ, Zamoshnikova A, Boucher D, Massey NL, et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat Chem Biol. 2019;15(6):556\u20139.","journal-title":"Nat Chem Biol"},{"issue":"7","key":"513_CR80","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1042\/EBC20210021","volume":"65","author":"KA Ravichandran","year":"2021","unstructured":"Ravichandran KA, Heneka MT. Inflammasome activation in neurodegenerative diseases. Essays Biochem. 2021;65(7):885\u2013904.","journal-title":"Essays Biochem"},{"issue":"7","key":"513_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/biom10071017","volume":"10","author":"C Porro","year":"2020","unstructured":"Porro C, Cianciulli A, Panaro MA. The regulatory role of IL-10 in neurodegenerative diseases. Biomolecules. 2020;10(7):1017.","journal-title":"Biomolecules"},{"issue":"761","key":"513_CR82","doi-asserted-by":"publisher","first-page":"eadm8563","DOI":"10.1126\/scitranslmed.adm8563","volume":"16","author":"S Bido","year":"2024","unstructured":"Bido S, Nannoni M, Muggeo S, Gambar\u00e8 D, Ruffini G, Bellini E, et al. Microglia-specific IL-10 gene delivery inhibits neuroinflammation and neurodegeneration in a mouse model of Parkinson\u2019s disease. Sci Transl Med. 2024;16(761):eadm8563.","journal-title":"Sci Transl Med."},{"issue":"6","key":"513_CR83","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/mt.2009.17","volume":"17","author":"RL Boudreau","year":"2009","unstructured":"Boudreau RL, McBride JL, Martins I, Shen S, Xing Y, Carter BJ, et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington\u2019s disease mice. Mol Ther. 2009;17(6):1053\u201363.","journal-title":"Mol Ther"},{"issue":"11","key":"513_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115719","volume":"22","author":"T Numakawa","year":"2021","unstructured":"Numakawa T, Odaka H. Brain-derived neurotrophic factor signaling in the pathophysiology of Alzheimer\u2019s disease: beneficial effects of flavonoids for neuroprotection. Int J Mol Sci. 2021;22(11):5719.","journal-title":"Int J Mol Sci"},{"key":"513_CR85","doi-asserted-by":"publisher","first-page":"1247422","DOI":"10.3389\/fnmol.2023.1247422","volume":"16","author":"T Numakawa","year":"2023","unstructured":"Numakawa T, Kajihara R. Involvement of brain-derived neurotrophic factor signaling in the pathogenesis of stress-related brain diseases. Front Mol Neurosci.\u00a02023;16:1247422.","journal-title":"Front Mol Neurosci"},{"issue":"12","key":"513_CR86","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1091\/mbc.e09-02-0168","volume":"20","author":"Y Hashimoto","year":"2009","unstructured":"Hashimoto Y, Kurita M, Aiso S, Nishimoto I, Matsuoka M. Humanin inhibits neuronal cell death by interacting with a cytokine receptor complex or complexes involving CNTF receptor alpha\/WSX-1\/gp130. Mol Biol Cell. 2009;20(12):2864\u201373.","journal-title":"Mol Biol Cell"},{"key":"513_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116691","volume":"175","author":"N Naimi","year":"2024","unstructured":"Naimi N, Seyedmirzaei H, Hassannejad Z, Soltani Khaboushan A. Advanced nanoparticle strategies for optimizing RNA therapeutic delivery in neurodegenerative disorders. Biomed Pharmacother. 2024;175:116691.","journal-title":"Biomed Pharmacother"},{"key":"513_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2024.100826","volume":"40","author":"HN Frazier","year":"2024","unstructured":"Frazier HN, Braun DJ, Bailey CS, Coleman MJ, Davis VA, Dundon SR, et al. A small molecule p38alpha MAPK inhibitor, MW150, attenuates behavioral deficits and neuronal dysfunction in a mouse model of mixed amyloid and vascular pathologies. Brain Behav Immun Health. 2024;40:100826.","journal-title":"Brain Behav Immun Health"},{"issue":"2","key":"513_CR89","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3892\/mmr.2020.11220","volume":"22","author":"L Jiang","year":"2020","unstructured":"Jiang L, Xu Z, Li H, Wu M, Wang F, Liu S, et al. TAK-242 exerts a neuroprotective effect via suppression of the TLR4\/MyD88\/TRIF\/NF-kappaB signaling pathway in a neonatal hypoxic-ischemic encephalopathy rat model. Mol Med Rep. 2020;22(2):1440\u20138.","journal-title":"Mol Med Rep"},{"issue":"1","key":"513_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01330-6","volume":"15","author":"D Balu","year":"2023","unstructured":"Balu D, Valencia-Olvera AC, Nguyen A, Patnam M, York J, Peri F, et al. A small-molecule TLR4 antagonist reduced neuroinflammation in female E4FAD mice. Alzheimers Res Ther. 2023;15(1):181.","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"513_CR91","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","volume":"13","author":"Z Wang","year":"2023","unstructured":"Wang Z, Li H, Gou L, Li W, Wang Y. Antibody-drug conjugates: recent advances in payloads. Acta Pharm Sin B. 2023;13(10):4025\u201359.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"513_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01481-w","volume":"8","author":"D Wu","year":"2023","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood\u2013brain barrier: structure, regulation and drug delivery. Signal Transduct Target Ther. 2023;8(1):217.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"513_CR93","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.neuron.2014.11.020","volume":"85","author":"P Chakrabarty","year":"2015","unstructured":"Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B, et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron. 2015;85(3):519\u201333.","journal-title":"Neuron"},{"key":"513_CR94","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.neuroscience.2020.03.008","volume":"437","author":"Y He","year":"2020","unstructured":"He Y, Gao Y, Zhang Q, Zhou G, Cao F, Yao S. IL-4 switches microglia\/macrophage M1\/M2 polarization and alleviates neurological damage by modulating the JAK1\/STAT6 pathway following ICH. Neuroscience. 2020;437:161\u201371.","journal-title":"Neuroscience"},{"key":"513_CR95","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3389\/fnins.2020.00441","volume":"14","author":"DA Dionisio-Santos","year":"2020","unstructured":"Dionisio-Santos DA, Behrouzi A, Olschowka JA, O\u2019Banion MK. Evaluating the effect of interleukin-4 in the 3xTg mouse model of Alzheimer\u2019s disease. Front Neurosci. 2020;14:441.","journal-title":"Front Neurosci"},{"issue":"8","key":"513_CR96","doi-asserted-by":"publisher","first-page":"e2309225","DOI":"10.1002\/adma.202309225","volume":"36","author":"WT Ralvenius","year":"2024","unstructured":"Ralvenius WT, Andresen JL, Huston MM, Penney J, Bonner JM, Fenton OS, et al. Nanoparticle-mediated delivery of anti-PU.1 siRNA via localized intracisternal administration reduces neuroinflammation. Adv Mater. 2024;36(8):e2309225.","journal-title":"Adv Mater"},{"key":"513_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.155150","volume":"122","author":"V Nayak","year":"2024","unstructured":"Nayak V, Patra S, Rout S, Jena AB, Sharma R, Pattanaik KP, et al. Regulation of neuroinflammation in Alzheimer\u2019s disease via nanoparticle-loaded phytocompounds with anti-inflammatory and autophagy-inducing properties. Phytomedicine. 2024;122:155150.","journal-title":"Phytomedicine"},{"issue":"3","key":"513_CR98","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/cells14030168","volume":"14","author":"E Lee","year":"2025","unstructured":"Lee E, Chang Y. Modulating neuroinflammation as a prospective therapeutic target in Alzheimer\u2019s disease. Cells.\u00a02025;14(3):168.","journal-title":"Cells"},{"issue":"6","key":"513_CR99","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.copbio.2011.06.007","volume":"22","author":"T Romer","year":"2011","unstructured":"Romer T, Leonhardt H, Rothbauer U. Engineering antibodies and proteins for molecular in vivo imaging. Curr Opin Biotechnol. 2011;22(6):882\u20137.","journal-title":"Curr Opin Biotechnol"},{"issue":"1","key":"513_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-025-00465-w","volume":"14","author":"B-H Kim","year":"2025","unstructured":"Kim B-H, Kim S, Nam Y, Park YH, Shin SM, Moon M. Second-generation anti-amyloid monoclonal antibodies for Alzheimer\u2019s disease: current landscape and future perspectives. Transl Neurodegener. 2025;14(1):6.","journal-title":"Transl Neurodegener"},{"issue":"11","key":"513_CR101","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1158\/1535-7163.MCT-22-0804","volume":"22","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP. Use of payload binding selectivity enhancers to improve therapeutic index of maytansinoid\u2013antibody\u2013drug conjugates. Mol Cancer Ther. 2023;22(11):1332\u201342.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"513_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/ph13110394","volume":"13","author":"WM Pardridge","year":"2020","unstructured":"Pardridge WM. Treatment of Alzheimer\u2019s disease and blood\u2013brain barrier drug delivery. Pharmaceuticals. 2020;13(11):394.","journal-title":"Pharmaceuticals"},{"key":"513_CR103","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jconrel.2019.02.023","volume":"299","author":"Y De Vlaeminck","year":"2019","unstructured":"De Vlaeminck Y, Lecocq Q, Giron P, Heirman C, Geeraerts X, Bolli E, et al. Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages. J Control Release. 2019;299:107\u201320.","journal-title":"J Control Release"},{"issue":"2","key":"513_CR104","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1021\/acschembio.3c00521","volume":"19","author":"R Jha","year":"2024","unstructured":"Jha R, Kinna A, Hotblack A, Bughda R, Bulek A, Gannon I, et al. Designer small-molecule control system based on minocycline-induced disruption of protein\u2013protein interaction. ACS Chem Biol. 2024;19(2):308\u201324.","journal-title":"ACS Chem Biol"},{"issue":"1","key":"513_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-31568-x","volume":"13","author":"AS Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 AS, Dias JNR, Aguiar S, Nogueira S, Bule P, Carvalho JI, et al. Rabbit derived VL single-domains as promising scaffolds to generate antibody\u2013drug conjugates. Sci Rep. 2023;13(1):4837.","journal-title":"Sci Rep"},{"issue":"12","key":"513_CR106","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117(12):1736\u201342.","journal-title":"Br J Cancer"},{"issue":"2","key":"513_CR107","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/pharmaceutics14020396","volume":"14","author":"R Sheyi","year":"2022","unstructured":"Sheyi R, de la Torre BG, Albericio F. Linkers: an assurance for controlled delivery of antibody-drug conjugate. Pharmaceutics.\u00a02022;14(2):396.","journal-title":"Pharmaceutics"},{"issue":"9","key":"513_CR108","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1158\/1535-7163.MCT-22-0362","volume":"21","author":"SYY Ha","year":"2022","unstructured":"Ha SYY, Anami Y, Yamazaki CM, Xiong W, Haase CM, Olson SD, et al. An enzymatically cleavable tripeptide linker for maximizing the therapeutic index of antibody-drug conjugates. Mol Cancer Ther. 2022;21(9):1449\u201361.","journal-title":"Mol Cancer Ther"},{"key":"513_CR109","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejps.2016.12.011","volume":"99","author":"SJ Sonawane","year":"2017","unstructured":"Sonawane SJ, Kalhapure RS, Govender T. Hydrazone linkages in pH responsive drug delivery systems. Eur J Pharm Sci. 2017;99:45\u201365.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"513_CR110","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s13346-021-00977-8","volume":"11","author":"Z Deng","year":"2021","unstructured":"Deng Z, Liu S. Inflammation-responsive delivery systems for the treatment of chronic inflammatory diseases. Drug Deliv Transl Res. 2021;11(4):1475\u201397.","journal-title":"Drug Deliv Transl Res"},{"key":"513_CR111","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.nbt.2019.04.002","volume":"52","author":"P Murer","year":"2019","unstructured":"Murer P, Neri D. Antibody-cytokine fusion proteins: a novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation. N Biotechnol. 2019;52:42\u201353.","journal-title":"N Biotechnol"},{"issue":"10","key":"513_CR112","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1096\/fj.11-201384","volume":"26","author":"T Li","year":"2012","unstructured":"Li T, Bourgeois J-P, Celli S, Glacial F, Le Sourd A-M, Mecheri S, et al. Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging. FASEB J. 2012;26(10):3969\u201379.","journal-title":"FASEB J"},{"key":"513_CR113","doi-asserted-by":"publisher","first-page":"1227816","DOI":"10.3389\/fddev.2023.1227816","volume":"3","author":"WM Pardridge","year":"2023","unstructured":"Pardridge WM. Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier. Front Drug Deliv.\u00a02023:3:1227816.","journal-title":"Front Drug Deliv"},{"issue":"3","key":"513_CR114","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12782","volume":"48","author":"C Kurz","year":"2022","unstructured":"Kurz C, Walker L, Rauchmann BS, Perneczky R. Dysfunction of the blood-brain barrier in Alzheimer\u2019s disease: evidence from human studies. Neuropathol Appl Neurobiol. 2022;48(3):e12782.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"22","key":"513_CR115","doi-asserted-by":"publisher","first-page":"16288","DOI":"10.3390\/ijms242216288","volume":"24","author":"AE Alkhalifa","year":"2023","unstructured":"Alkhalifa AE, Al-Ghraiybah NF, Odum J, Shunnarah JG, Austin N, Kaddoumi A. Blood-brain barrier breakdown in Alzheimer\u2019s disease: mechanisms and targeted strategies. Int J Mol Sci.\u00a02023;24(22):16288.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"513_CR116","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3390\/pharmaceutics15030768","volume":"15","author":"MG Manuel","year":"2023","unstructured":"Manuel MG, Tamba BI, Leclere M, Mabrouk M, Schreiner TG, Ciobanu R, et al. Intrathecal pseudodelivery of drugs in the therapy of neurodegenerative diseases: rationale, basis and potential applications. Pharmaceutics.\u00a02023;15(3):768.","journal-title":"Pharmaceutics"},{"issue":"6","key":"513_CR117","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.cell.2025.01.017","volume":"188","author":"H Shen","year":"2025","unstructured":"Shen H, Aggarwal N, Cui B, Foo GW, He Y, Srivastava SK, et al. Engineered commensals for targeted nose-to-brain drug delivery. Cell.\u00a02025;188(6):1545-562.e16.","journal-title":"Cell"},{"issue":"4","key":"513_CR118","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2200057120","volume":"120","author":"D Correa","year":"2023","unstructured":"Correa D, Scheuber MI, Shan H, Weinmann OW, Baumgartner YA, Harten A, et al. Intranasal delivery of full-length anti-Nogo-A antibody: a potential alternative route for therapeutic antibodies to central nervous system targets. Proc Natl Acad Sci U S A. 2023;120(4):e2200057120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"51","key":"513_CR119","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2304213120","volume":"120","author":"H Zhang","year":"2023","unstructured":"Zhang H, Chen Y, Yu M, Xi Y, Han G, Jin Y, et al. Nasal delivery of polymeric nanoDisc mobilizes a synergy of central and peripheral amyloid-beta clearance to treat Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2023;120(51):e2304213120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"513_CR120","doi-asserted-by":"publisher","first-page":"1360302","DOI":"10.3389\/fddev.2024.1360302","volume":"4","author":"AS Haqqani","year":"2024","unstructured":"Haqqani AS, B\u00e9langer K, Stanimirovic DB. Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria. Frontiers in Drug Delivery. 2024;4:1360302.","journal-title":"Frontiers in Drug Delivery."},{"key":"513_CR121","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3389\/fnins.2018.01019","volume":"12","author":"VM Pulgar","year":"2019","unstructured":"Pulgar VM. Transcytosis to cross the blood brain barrier, new advancements and challenges. Front Neurosci.\u00a02019:12:1019.","journal-title":"Front Neurosci"},{"issue":"4","key":"513_CR122","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/abt\/tbac028","volume":"5","author":"P Zhao","year":"2022","unstructured":"Zhao P, Zhang N, An Z. Engineering antibody and protein therapeutics to cross the blood-brain barrier. Antibody Therapeutics. 2022;5(4):311\u201331.","journal-title":"Antibody Therapeutics"},{"issue":"7","key":"513_CR123","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nri3705","volume":"14","author":"MT Heneka","year":"2014","unstructured":"Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014;14(7):463\u201377.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"513_CR124","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-024-00730-y","volume":"19","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Lin Y, Tetlow AM, Pan R, Ji C, Kong X-P, et al. Single-domain antibody-based protein degrader for synucleinopathies. Mol Neurodegener. 2024;19(1):44.","journal-title":"Mol Neurodegener"},{"key":"513_CR125","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3389\/fncel.2014.00344","volume":"8","author":"B Rissiek","year":"2014","unstructured":"Rissiek B, Koch-Nolte F, Magnus T. Nanobodies as modulators of inflammation: potential applications for acute brain injury. Front Cell Neurosci. 2014;8:344.","journal-title":"Front Cell Neurosci"},{"issue":"2","key":"513_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/antib8020027","volume":"8","author":"K B\u00e9langer","year":"2019","unstructured":"B\u00e9langer K, Iqbal U, Tanha J, MacKenzie R, Moreno M, Stanimirovic D. Single-domain antibodies as therapeutic and imaging agents for the treatment of CNS diseases. Antibodies (Basel). 2019;8(2):27.","journal-title":"Antibodies (Basel)"},{"issue":"3","key":"513_CR127","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032632","volume":"24","author":"ME Tsitokana","year":"2023","unstructured":"Tsitokana ME, Lafon P-A, Pr\u00e9zeau L, Pin J-P, Rondard P. Targeting the brain with single-domain antibodies: greater potential than stated so far? Int J Mol Sci. 2023;24(3):2632.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"513_CR128","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","volume":"22","author":"E Alexander","year":"2024","unstructured":"Alexander E, Leong KW. Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years. J Nanobiotechnology. 2024;22(1):661.","journal-title":"J Nanobiotechnology"},{"key":"513_CR129","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3389\/fimmu.2021.632687","volume":"12","author":"C Ackaert","year":"2021","unstructured":"Ackaert C, Smiejkowska N, Xavier C, Sterckx YGJ, Denies S, Stijlemans B, et al. Immunogenicity risk profile of nanobodies. Front Immunol. 2021;12:2021.","journal-title":"Front Immunol"},{"issue":"1","key":"513_CR130","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","volume":"34","author":"I Jov\u010devska","year":"2020","unstructured":"Jov\u010devska I, Muyldermans S. The therapeutic potential of nanobodies. BioDrugs. 2020;34(1):11\u201326.","journal-title":"BioDrugs"},{"issue":"1","key":"513_CR131","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/1471-2377-9-S1-S2","volume":"9","author":"KL Steinmetz","year":"2009","unstructured":"Steinmetz KL, Spack EG. The basics of preclinical drug development for neurodegenerative disease indications. BMC Neurol. 2009;9(1):S2.","journal-title":"BMC Neurol"},{"issue":"1","key":"513_CR132","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01599-1","volume":"16","author":"H Long","year":"2024","unstructured":"Long H, Simmons A, Mayorga A, Burgess B, Nguyen T, Budda B, et al. Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16(1):235.","journal-title":"Alzheimers Res Ther"},{"issue":"17","key":"513_CR133","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202210879","volume":"35","author":"L Zhao","year":"2023","unstructured":"Zhao L, Meng F, Li Y, Liu S, Xu M, Chu F, et al. Multivalent nanobody conjugate with rigid, reactive oxygen species scavenging scaffold for multi-target therapy of Alzheimer\u2019s disease. Adv Mater. 2023;35(17):e2210879.","journal-title":"Adv Mater"},{"issue":"1","key":"513_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66970-6","volume":"14","author":"JR Haynes","year":"2024","unstructured":"Haynes JR, Whitmore CA, Behof WJ, Landman CA, Ong HH, Feld AP, et al. Targeting soluble amyloid-beta oligomers with a novel nanobody. Sci Rep. 2024;14(1):16086.","journal-title":"Sci Rep"},{"issue":"6","key":"513_CR135","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1080\/19420862.2017.1342914","volume":"9","author":"M Vandesquille","year":"2017","unstructured":"Vandesquille M, Li T, Po C, Ganneau C, Lenormand P, Dudeffant C, et al. Chemically-defined camelid antibody bioconjugate for the magnetic resonance imaging of Alzheimer\u2019s disease. MAbs. 2017;9(6):1016\u201327.","journal-title":"MAbs"},{"key":"513_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2016.09.019","volume":"243","author":"T Li","year":"2016","unstructured":"Li T, Vandesquille M, Koukouli F, Dudeffant C, Youssef I, Lenormand P, et al. Camelid single-domain antibodies: a versatile tool for in vivo imaging of extracellular and intracellular brain targets. J Control Release. 2016;243:1\u201310.","journal-title":"J Control Release"},{"issue":"3","key":"513_CR137","first-page":"169","volume":"2","author":"J Ferrero","year":"2016","unstructured":"Ferrero J, Williams L, Stella H, Leitermann K, Mikulskis A, O\u2019Gorman J, et al. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia: Trans Res Clinical Intervent. 2016;2(3):169\u201376.","journal-title":"Alzheimer\u2019s & Dementia: Trans Res Clinical Intervent."},{"issue":"1","key":"513_CR138","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12112","volume":"7","author":"SL Lowe","year":"2021","unstructured":"Lowe SL, Willis BA, Hawdon A, Natanegara F, Chua L, Foster J, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer\u2019s disease.\u00a0Alzheimers Dement (N Y). 2021;7(1):e12112.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"5","key":"513_CR139","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.tibtech.2014.03.001","volume":"32","author":"T De Meyer","year":"2014","unstructured":"De Meyer T, Muyldermans S, Depicker A. Nanobody-based products as research and diagnostic tools. Trends Biotechnol. 2014;32(5):263\u201370.","journal-title":"Trends Biotechnol"},{"key":"513_CR140","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-animal-021419-083831","volume":"9","author":"S Muyldermans","year":"2021","unstructured":"Muyldermans S. Applications of nanobodies. Annu Rev Anim Biosci. 2021;9:401\u201321.","journal-title":"Annu Rev Anim Biosci"},{"key":"513_CR141","doi-asserted-by":"crossref","unstructured":"Saerens D, Muyldermans S. Single Domain Antibodies: Methods and Protocols. New York : Humana Press; Springer, c2012.","DOI":"10.1007\/978-1-61779-968-6"},{"issue":"5","key":"513_CR142","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1021\/cr500399p","volume":"115","author":"O Boutureira","year":"2015","unstructured":"Boutureira O, Bernardes GJL. Advances in chemical protein modification. Chem Rev. 2015;115(5):2174\u201395.","journal-title":"Chem Rev"},{"issue":"5","key":"513_CR143","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1021\/jacsau.2c00617","volume":"3","author":"A Debon","year":"2023","unstructured":"Debon A, Siirola E, Snajdrova R. Enzymatic bioconjugation: a perspective from the pharmaceutical industry. JACS Au. 2023;3(5):1267\u201383.","journal-title":"JACS Au"},{"key":"513_CR144","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","volume":"8","author":"P Bannas","year":"2017","unstructured":"Bannas P, Hambach J, Koch-Nolte F. Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics. Front Immunol. 2017;8:1603.","journal-title":"Front Immunol"},{"issue":"4","key":"513_CR145","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809824","volume":"14","author":"M Marino","year":"2022","unstructured":"Marino M, Zhou L, Rincon MY, Callaerts-Vegh Z, Verhaert J, Wahis J, et al. Aav-mediated delivery of an anti-BACE1 VHH alleviates pathology in an Alzheimer\u2019s disease model. EMBO Mol Med. 2022;14(4):e09824.","journal-title":"EMBO Mol Med"},{"issue":"5","key":"513_CR146","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1177\/0271678X211035625","volume":"42","author":"MS Kang","year":"2022","unstructured":"Kang MS, Shin M, Ottoy J, Aliaga AA, Mathotaarachchi S, Quispialaya K, et al. Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer\u2019s disease therapeutic. J Cereb Blood Flow Metab. 2022;42(5):788\u2013801.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"4","key":"513_CR147","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.ymthe.2022.01.009","volume":"30","author":"C Danis","year":"2022","unstructured":"Danis C, Dupr\u00e9 E, Zejneli O, Caillierez R, Arrial A, B\u00e9gard S, et al. Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment. Mol Ther. 2022;30(4):1484\u201399.","journal-title":"Mol Ther"},{"issue":"41","key":"513_CR148","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2300258120","volume":"120","author":"R Abskharon","year":"2023","unstructured":"Abskharon R, Pan H, Sawaya MR, Seidler PM, Olivares EJ, Chen Y, et al. Structure-based design of nanobodies that inhibit seeding of Alzheimer\u2019s patient-extracted tau fibrils. Proc Natl Acad Sci U S A. 2023;120(41):e2300258120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"513_CR149","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3343\/alm.2021.41.6.549","volume":"41","author":"TS Pillay","year":"2021","unstructured":"Pillay TS, Muyldermans S. Application of single-domain antibodies (\u201cnanobodies\u201d) to laboratory diagnosis. Ann Lab Med. 2021;41(6):549\u201358.","journal-title":"Ann Lab Med"},{"issue":"1","key":"513_CR150","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41591-023-02639-3","volume":"30","author":"CJ Mummery","year":"2024","unstructured":"Mummery CJ, Borjesson-Hanson A, Blackburn DJ, Vijverberg EGB, De Deyn PP, Ducharme S, et al. Author Correction: Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer\u2019s disease: a phase 1b, randomized, placebo-controlled trial. Nat Med. 2024;30(1):304.","journal-title":"Nat Med"},{"issue":"754","key":"513_CR151","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj5958","volume":"16","author":"S Gaikwad","year":"2024","unstructured":"Gaikwad S, Puangmalai N, Sonawane M, Montalbano M, Price R, Iyer MS, et al. Nasal tau immunotherapy clears intracellular tau pathology and improves cognitive functions in aged tauopathy mice. Sci Transl Med. 2024;16(754):eadj5958.","journal-title":"Sci Transl Med"},{"issue":"6712","key":"513_CR152","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1126\/science.adp5186","volume":"385","author":"J Benn","year":"2024","unstructured":"Benn J, Cheng S, Keeling S, Smith AE, Vaysburd MJ, B\u00f6ken D, et al. Aggregate-selective removal of pathological tau by clustering-activated degraders. Science. 2024;385(6712):1009\u201316.","journal-title":"Science"},{"key":"513_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.imu.2024.101526","volume":"48","author":"N Aftab","year":"2024","unstructured":"Aftab N, Masood F, Ahmad S, Rahim SS, Sanami S, Shaker B, et al. An optimized deep learning approach for blood-brain barrier permeability prediction with ODE integration. Inf Med Unlocked. 2024;48:101526.","journal-title":"Inf Med Unlocked"},{"key":"513_CR154","doi-asserted-by":"publisher","first-page":"858126","DOI":"10.3389\/fnins.2022.858126","volume":"16","author":"R Kumar","year":"2022","unstructured":"Kumar R, Sharma A, Alexiou A, Bilgrami AL, Kamal MA, Ashraf GM. Deeppred-BBB: a blood brain barrier permeability prediction model with improved accuracy. Front Neurosci.\u00a02022:16:858126.","journal-title":"Front Neurosci"}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-025-00513-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-025-00513-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-025-00513-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T16:04:16Z","timestamp":1760371456000},"score":1,"resource":{"primary":{"URL":"https:\/\/translationalneurodegeneration.biomedcentral.com\/articles\/10.1186\/s40035-025-00513-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":154,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["513"],"URL":"https:\/\/doi.org\/10.1186\/s40035-025-00513-5","relation":{},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate."}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research was supported [in part] by the Intramural Research Program of the National Institutes of Health (NIH). The contributions of the NIH author(s) are considered Works of the United States Government. The findings and conclusions presented in this paper are those of the author(s) and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"51"}}